Trial Profile
Personalized Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors: A Phase 2 Study
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Jun 2023
Price :
$35
*
At a glance
- Drugs Lutetium-(177Lu)-oxodotreotide (Primary)
- Indications Neuroendocrine tumours
- Focus Therapeutic Use
- Acronyms P-PRRT
- 31 May 2023 Planned End Date changed from 1 Dec 2026 to 12 Apr 2029.
- 31 May 2023 Planned primary completion date changed from 1 Apr 2021 to 12 Apr 2025.
- 15 Jul 2020 Planned number of patients changed from 85 to 300.